Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura

“…It has also been revealed that patients on caplacizumab are less likely to develop refractory disease [40,41]. However, the relapse rate is reported to be higher amongst the patients on caplacizumab as compared to the placebo [41]. It is evident from this review that caplacizumab is associated with some adverse effects as well.…”

“…Our review included seven articles and involves a comprehensive assessment of the beneficial and adverse effects of this drug. The results of our literature review suggest that caplacizumab helps in normalizing the platelet counts at a faster rate and to a greater extent as compared to the placebo [39][40][41][42]. Patients of TTP on caplacizumab need less plasma exchange to show an improved outcome [21,39,40,42].…”

“…Most importantly, caplacizumab is associated with a high complete remission rate and a low recurrence of this autoimmune disorder [21,39,42]. It has also been revealed that patients on caplacizumab are less likely to develop refractory disease [40,41]. However, the relapse rate is reported to be higher amongst the patients on caplacizumab as compared to the placebo [41].…”

“…The study by Peyvandi et al has also revealed that caplacizumab is associated with quick resolution of thrombocytopenia [39]. It has been reported that caplacizumab results in 39% faster normalization of platelet counts (p=0.005) [39][40][41].…”

“…A relapse is an acute flare of TTP occurring after one month of plasma exchange therapy [40]. It has been reported in a study that 11 patients (out of 35) in the caplacizumab group, as compared to three (out of 37) in the placebo group, had a relapse during the follow-up [41]. This study is backed by another study showed that eight (out of 35) patients who received caplacizumab and zero patient who received placebo group relapsed within thirty days [40].…”